Kiyoko Takane, Tingwei Cai, Rei Noguchi, Yoshimasa Gohda, Tsuneo Ikenoue, Kiyoshi Yamaguchi, Yasunori Ota, Tomomichi Kiyomatsu, Hideaki Yano, Masaki Fukuyo, Motoaki Seki, Rahmutulla Bahityar, Atsushi Kaneda, Yoichi Furukawa
INTRODUCTION: Pseudomyxoma peritonei (PMP) is a disease characterized by progressive accumulation of intraperitoneal mucinous ascites produced by neoplasms in the abdominal cavity. Since the prognosis of patients with PMP remain unsatisfactory, the development of effective therapeutic drug(s) is a matter of pressing concern. Genetic analyses of PMP have clarified the frequent activation of GNAS and/or KRAS. However, the involvement of global epigenetic alterations in PMPs has not been reported...
January 23, 2024: Oncology